This opens the possibility to add a wide range of anti-tumor mediators in addition to the “naturally occurring” anti-tumor mediators in MCs (already demonstrated to shrink tumors and extend lifespan) to develop a “super killing” cell for cancer (or other malignancies in which there are IgE targets) immunotherapy. Here, IGHE is linked to neoplasm.